Danielle Antalffy
Stock Analyst at UBS
(3.34)
# 936
Out of 4,784 analysts
170
Total ratings
44.86%
Success rate
3.08%
Average return
Main Sectors:
Stocks Rated by Danielle Antalffy
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MDT Medtronic | Maintains: Neutral | $85 → $95 | $87.63 | +8.41% | 8 | Feb 19, 2025 | |
| BSX Boston Scientific | Maintains: Buy | $105 → $130 | $99.36 | +30.84% | 12 | Feb 7, 2025 | |
| SGHT Sight Sciences | Maintains: Buy | $5.5 → $5 | $2.55 | +96.08% | 2 | Jan 27, 2025 | |
| ABT Abbott Laboratories | Maintains: Buy | $146 → $148 | $130.82 | +13.13% | 12 | Jan 23, 2025 | |
| RXST RxSight | Initiates: Buy | $52 | $26.56 | +95.78% | 2 | Dec 6, 2024 | |
| GKOS Glaukos | Initiates: Buy | $182 | $102.00 | +78.43% | 1 | Dec 6, 2024 | |
| SYK Stryker | Maintains: Neutral | $366 → $370 | $364.50 | +1.51% | 6 | Oct 30, 2024 | |
| ATRC AtriCure | Maintains: Buy | $35 → $40 | $31.83 | +25.67% | 12 | Oct 30, 2024 | |
| EW Edwards Lifesciences | Maintains: Neutral | $90 → $75 | $70.91 | +5.77% | 12 | Sep 10, 2024 | |
| ZBH Zimmer Biomet Holdings | Maintains: Sell | $112 → $107 | $112.26 | -4.69% | 4 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $6.5 → $7 | $8.45 | -17.16% | 5 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $163 → $95 | $67.74 | +40.24% | 8 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $24 → $26 | $17.70 | +46.89% | 3 | Feb 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $75 | $37.76 | +98.62% | 1 | Jan 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $180 | $163.71 | +9.95% | 4 | Dec 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $405 → $322 | $157.24 | +104.78% | 5 | Sep 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $2.25 | $2.37 | -5.06% | 1 | Mar 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $43 | $33.75 | +27.41% | 5 | Mar 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $278 | $491.84 | -43.48% | 1 | Mar 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $45 | $19.28 | +133.40% | 14 | Mar 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $300 → $280 | $258.75 | +8.21% | 12 | May 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $975 → $825 | $12.58 | +6,458.03% | 2 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $14 | $18.36 | -23.75% | 1 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $75 → $100 | $96.16 | +3.99% | 2 | May 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $12 | $11.85 | +1.27% | 3 | Mar 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $30 | $60.05 | -50.04% | 3 | Mar 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $45 | $44.50 | +1.12% | 4 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $105 → $85 | $5.84 | +1,355.48% | 10 | Feb 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $270 → $275 | $227.50 | +20.88% | 1 | Feb 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $26 → $20 | $4.50 | +344.44% | 3 | Nov 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $72 → $42 | $6.80 | +517.65% | 7 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $3 | $0.68 | +344.12% | 3 | Apr 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $15 | $1.00 | +1,400.00% | 1 | Sep 1, 2020 |
Medtronic
Feb 19, 2025
Maintains: Neutral
Price Target: $85 → $95
Current: $87.63
Upside: +8.41%
Boston Scientific
Feb 7, 2025
Maintains: Buy
Price Target: $105 → $130
Current: $99.36
Upside: +30.84%
Sight Sciences
Jan 27, 2025
Maintains: Buy
Price Target: $5.5 → $5
Current: $2.55
Upside: +96.08%
Abbott Laboratories
Jan 23, 2025
Maintains: Buy
Price Target: $146 → $148
Current: $130.82
Upside: +13.13%
RxSight
Dec 6, 2024
Initiates: Buy
Price Target: $52
Current: $26.56
Upside: +95.78%
Glaukos
Dec 6, 2024
Initiates: Buy
Price Target: $182
Current: $102.00
Upside: +78.43%
Stryker
Oct 30, 2024
Maintains: Neutral
Price Target: $366 → $370
Current: $364.50
Upside: +1.51%
AtriCure
Oct 30, 2024
Maintains: Buy
Price Target: $35 → $40
Current: $31.83
Upside: +25.67%
Edwards Lifesciences
Sep 10, 2024
Maintains: Neutral
Price Target: $90 → $75
Current: $70.91
Upside: +5.77%
Zimmer Biomet Holdings
Aug 8, 2024
Maintains: Sell
Price Target: $112 → $107
Current: $112.26
Upside: -4.69%
Aug 7, 2024
Maintains: Neutral
Price Target: $6.5 → $7
Current: $8.45
Upside: -17.16%
Jul 26, 2024
Maintains: Buy
Price Target: $163 → $95
Current: $67.74
Upside: +40.24%
Feb 14, 2024
Maintains: Neutral
Price Target: $24 → $26
Current: $17.70
Upside: +46.89%
Jan 22, 2024
Initiates: Buy
Price Target: $75
Current: $37.76
Upside: +98.62%
Dec 1, 2023
Upgrades: Buy
Price Target: $180
Current: $163.71
Upside: +9.95%
Sep 6, 2023
Maintains: Buy
Price Target: $405 → $322
Current: $157.24
Upside: +104.78%
Mar 29, 2023
Initiates: Neutral
Price Target: $2.25
Current: $2.37
Upside: -5.06%
Mar 29, 2023
Initiates: Neutral
Price Target: $43
Current: $33.75
Upside: +27.41%
Mar 29, 2023
Initiates: Neutral
Price Target: $278
Current: $491.84
Upside: -43.48%
Mar 29, 2023
Initiates: Neutral
Price Target: $45
Current: $19.28
Upside: +133.40%
May 6, 2022
Maintains: Outperform
Price Target: $300 → $280
Current: $258.75
Upside: +8.21%
May 5, 2022
Maintains: Outperform
Price Target: $975 → $825
Current: $12.58
Upside: +6,458.03%
May 5, 2022
Maintains: Outperform
Price Target: $12 → $14
Current: $18.36
Upside: -23.75%
May 2, 2022
Maintains: Outperform
Price Target: $75 → $100
Current: $96.16
Upside: +3.99%
Mar 11, 2022
Maintains: Outperform
Price Target: $15 → $12
Current: $11.85
Upside: +1.27%
Mar 9, 2022
Maintains: Outperform
Price Target: $25 → $30
Current: $60.05
Upside: -50.04%
Feb 25, 2022
Maintains: Outperform
Price Target: $40 → $45
Current: $44.50
Upside: +1.12%
Feb 24, 2022
Maintains: Outperform
Price Target: $105 → $85
Current: $5.84
Upside: +1,355.48%
Feb 4, 2022
Maintains: Market Perform
Price Target: $270 → $275
Current: $227.50
Upside: +20.88%
Nov 10, 2021
Maintains: Outperform
Price Target: $26 → $20
Current: $4.50
Upside: +344.44%
Nov 5, 2021
Maintains: Market Perform
Price Target: $72 → $42
Current: $6.80
Upside: +517.65%
Apr 1, 2021
Downgrades: Market Perform
Price Target: $3
Current: $0.68
Upside: +344.12%
Sep 1, 2020
Initiates: Outperform
Price Target: $15
Current: $1.00
Upside: +1,400.00%